What the clinical trials actually found Six randomized, double-blind, placebo-controlled trials involving over 900 participants have evaluated AOD 9604 in humans
Statistically non-significant, clinically uninteresting
The synthetic origin is not a weakness
This efficacy limitation, rather than safety concerns, halted further development
1% GHK-Cu with 1% Acetyl Tetrapeptide-3 AHK-Cu vs GHK-Cu: Side-by-Side Comparison While the main difference between GHK-Cu and AHK-Cu lies in their structure, their diverging effects and research history paint a larger picture: What's the Difference Between GHK-Cu and AHK-Cu
GLP-1 agonists commonly cause nausea, vomiting, and gastrointestinal distress, particularly during dose escalation